{"title":"雄激素受体(AR)与乳腺癌:正常/良性乳腺腔细胞AR状态的参考","authors":"Xi Wang","doi":"10.14800/RCI.533","DOIUrl":null,"url":null,"abstract":"The role of androgen and androgen receptor pathway in breast cancer development, prognosis and treatment has gained enormous attentions in recent years, largely because of the effort to identify new markers for targeted treatment of triple (ER/PR/Her2) negative breast carcinomas. This mini-review will discuss AR and breast cancer from the perspectives of normal/benign breast luminal epithelium.","PeriodicalId":20980,"journal":{"name":"Receptors and clinical investigation","volume":"8 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Androgen Receptor (AR) and Breast Cancer: Reference to the AR Status in Normal/Benign Breast Luminal Cells\",\"authors\":\"Xi Wang\",\"doi\":\"10.14800/RCI.533\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The role of androgen and androgen receptor pathway in breast cancer development, prognosis and treatment has gained enormous attentions in recent years, largely because of the effort to identify new markers for targeted treatment of triple (ER/PR/Her2) negative breast carcinomas. This mini-review will discuss AR and breast cancer from the perspectives of normal/benign breast luminal epithelium.\",\"PeriodicalId\":20980,\"journal\":{\"name\":\"Receptors and clinical investigation\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-01-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Receptors and clinical investigation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14800/RCI.533\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Receptors and clinical investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14800/RCI.533","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Androgen Receptor (AR) and Breast Cancer: Reference to the AR Status in Normal/Benign Breast Luminal Cells
The role of androgen and androgen receptor pathway in breast cancer development, prognosis and treatment has gained enormous attentions in recent years, largely because of the effort to identify new markers for targeted treatment of triple (ER/PR/Her2) negative breast carcinomas. This mini-review will discuss AR and breast cancer from the perspectives of normal/benign breast luminal epithelium.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
